Neuroactive steroids and fatigue severity in patients with primary biliary cirrhosis and hepatitis C

Neurogastroenterology and Motility

Volumn 20, Issue 6, 2008, Pages 671-679

  Ahboucha, S ^a,b   Butterworth, R F ^a   Pomier Layrargues, G ^c   Vincent, C ^c   Hassoun, Z ^c   Baker, G B ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Allopregnanolone; Chronic hepatitis C; Fatigue; Neuroactive steroids; Pregnanolone; Primary biliary cirrhosis

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 3BETA HYDROXY 5BETA PREGNAN 20 ONE; 3BETA,5ALPHA TETRAHYDROPROGESTERONE; 4 AMINOBUTYRIC ACID A RECEPTOR; ELTANOLONE; ISOPREGNANOLONE; TETRAHYDRODEOXYCORTICOSTERONE; TETRAHYDROPROGESTERONE;

ADULT; ALLOSTERISM; ARTICLE; BILIARY CIRRHOSIS; BLOOD BRAIN BARRIER; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS C; HORMONE ACTION; HUMAN; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGESTERONE METABOLISM; STEROID BLOOD LEVEL;

EID: 43549089722     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2007.01080.x     Document Type: Article

References (47)

1. 1 Swain MG. Fatigue in chronic disease. Clin Sci (Lond) 2000 ; 99: 1–8.
2. 2 Huet PM, Deslauriers J, Tran A, Faucher C, Charbonneau J. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol 2000 ; 95: 760–7.
3. 3 Piche T, Gelsi E, Schneider SM et al. Fatigue is associated with high circulating leptin levels in chronic hepatitis C. Gut 2002 ; 51: 434–9.
4. 4 Goldblatt J, Taylor PJ, Lipman T et al. The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology 2002 ; 122: 1235–41.
5. 5 Hassoun Z, Willems B, Deslauriers J, Nguyen BN, Huet PM. Assessment of fatigue in patients with chronic hepatitis C using the fatigue impact scale (FIS). Dig Dis Sci 2002 ; 47: 2674–81.
6. 6 Burak KW, Le T, Swain MG. Increased sensitivity to the locomotor‐activating effects of corticotropin‐releasing hormone in cholestatic rats. Gastroenterology 2002 ; 122: 681–8.
7. 7 Swain MG, Maric M. Improvement in cholestasis‐associated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment. Hepatology 1997 ; 25: 291–4.
8. 8 Swain MG, Beck P, Rioux K, Le T. Augmented interleukin‐1beta‐induced depression of locomotor activity in cholestatic rats. Hepatology 1998 ; 28: 1561–5.
9. 9 Forton DM, Patel N, Prince M et al. Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels. Gut 2004 ; 53: 587–92.
10. 10 Jones EA. Relief from profound fatigue associated with chronic liver disease by long‐term ondansetron therapy. Lancet 1999 ; 354: 397.
11. 11 Piche T, Vanbiervliet G, Cherikh F et al. Effect of ondansetron, a 5‐HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study. Gut 2005 ; 54: 1169–73.
12. 12 Weissenborn K, Ennen JC, Bokemeyer M et al. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 2006 ; 55: 1624–30.
13. 13 Forton DM, Thomas HC, Murphy CA et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002 ; 35: 433–9.
14. 14 Weissenborn K, Krause J, Bokemeyer M et al. Hepatitis C virus infection affects the brain‐evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004 ; 41: 845–51.
15. 15 Gershon AS, Margulies M, Gorczynski RM. Heathcote EJ. Serum cytokine values and fatigue in chronic hepatitis C infection. J Viral Hepat 2000 ; 7: 397–402.
16. 16 Ahboucha S, Butterworth RF. The neurosteroid system: Implication in the pathophysiology of hepatic encephalopathy. Neurochem Int 2007 (in press).
17. 17 Korneyev A, Pan BS, Polo A, Romeo E, Guidotti A, Costa E. Stimulation of brain pregnenolone synthesis by mitochondrial diazepam binding inhibitor receptor ligands in vivo. J Neurochem 1993 ; 61: 1515–24.
18. 18 Rhodes ME, Harney JP, Frye CA. Gonadal, adrenal, and neuroactive steroids’ role in ictal activity. Brain Res 2004 ; 1000: 8–18.
19. 19 Murphy BE, Abbott FV, Allison CM, Watts C, Ghadirian AM. Elevated levels of some neuroactive progesterone metabolites, particularly isopregnanolone, in women with chronic fatigue syndrome. Psychoneuroendocrinology 2004 ; 29: 245–68.
20. 20 Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992 ; 6: 2311–22.
21. 21 Wang MD, Bäckström T, Landgren S. The inhibitory effects of allopregnanolone and pregnanolone on the population spike, evoked in the rat hippocampal CA1 stratum pyramidale in vitro, can be blocked selectively by epiallopregnanolone. Acta Physiol Scand 2000 ; 169: 333–41.
22. 22 Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994 ; 18 (Suppl. 1): S79–83.
23. 23 Kim YS, Zhang H, Kim HY. Profiling neurosteroids in cerebrospinal fluids and plasma by gas chromatography/electron capture negative chemical ionization mass spectrometry. Anal Biochem 2000 ; 277: 1871–95.
24. 24 Goh J, Coughlan B, Quinn J, O’Keane JC, Crowe J. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1999 ; 11: 833–8.
25. 25 Romeo E, Strohle A, Spalletta G et al. Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 1998 ; 155: 910–3.
26. 26 Epperson CN, Haga K, Mason GF et al. Cortical gamma‐aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 2002 ; 59: 851–8.
27. 27 Wang M, Seippel L, Purdy RH, Bãckström T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5‐alpha‐pregnane‐3,20‐dione and 3‐alpha‐hydroxy‐5‐alpha‐pregnan‐20‐one. J Clin Endocrinol Metab 1996 ; 81: 1076–82.
28. 28 Genazzani AR, Petraglia F, Bernardi F et al. Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. J Clin Endocrinol Metab 1998 ; 83: 2099–103.
29. 29 Zhu D, Wang MD, Backstrom T, Wahlstrom G. Evaluation and comparison of the pharmacokinetic and pharmacodynamic properties of allopregnanolone and pregnanolone at induction of anaesthesia in the male rat. Br J Anaesth 2001 ; 86: 403–12.
30. 30 Ahboucha S, Pomier‐Layrargues G, Vincent C et al. Reduced plasma dehydroepiandrosterone sulfate levels are significantly correlated with fatigue severity in patients with primary biliary cirrhosis. Neurochem Int 2007 (in press).
31. 31 Stanczyk FZ. All progestins are not created equal. Steroids 2003 ; 68: 879–90.
32. 32 Karagiannis A, Harsoulis F. Gonadal dysfunction in systemic diseases. Eur J Endocrinol 2005 ; 152: 501–13.
33. 33 Zietz B, Wengler I, Messmann H, Lock G, Scholmerich J, Straub RH. Early shifts of adrenal steroid synthesis before and after relief of short‐term cholestasis. J Hepatol 2001 ; 35: 329–37.
34. 34 Zietz B, Lock G, Plach B et al. Dysfunction of the hypothalamic‐pituitary‐glandular axes and relation to Child‐Pugh classification in male patients with alcoholic and virus‐related cirrhosis. Eur J Gastroenterol Hepatol 2003 ; 15: 495–501.
35. 35 Ghezzi P, Santo ED, Sacco S et al. Neurosteroid levels are increased in vivo after LPS treatment and negatively regulate LPS‐induced TNF production. Eur Cytokine Netw 2000 ; 11: 464–9.
36. 36 Aller R, De Luis DA, Moreira V et al. The effect of liver transplantation on circulating levels of estradiol and progesterone in male patients: parallelism with hepatopulmonary syndrome and systemic hyperdynamic circulation improvement. J Endocrinol Invest 2001 ; 24: 503–9.
37. 37 Farthing MJ, Green JR, Edwards CR, Dawson AM. Progesterone, prolactin, and gynaecomastia in men with liver disease. Gut 1982 ; 23: 276–9.
38. 38 Ahboucha S, Chatauret N, Mamer O, Butterworth RF. Increased brain concentrations of the potent neuroinhibitory steroids allopregnanolone and tetrahydrodeoxycorticosterone (THDOC) in rats with acute liver failure due to hepatic devascularization [abstract]. Hepatology 2004 ; 40 (Suppl.): 497A.
39. 39 Norenberg MD, Ltzhak Y, Bender AS. The peripheral benzodiazepine receptor and neurosteroids in hepatic encephalopathy. Adv Exp Med Biol 1997 ; 420: 95–111.
40. 40 Ahboucha S, Jiang W, Chatauret N, Mamer O, Baker BG, Butterworth RF. Indomethacin reverses locomotor deficit and reduces brain levels of neuroinhibitory steroids in rats following portacaval anastomosis [abstract]. Can J Gastroenterol 2007 ; 21 (Suppl. A) 83A.
41. 41 Ahboucha S, Layrargues GP, Mamer O, Butterworth RF. Increased brain concentrations of a neuroinhibitory steroid in human hepatic encephalopathy. Annals Neurol 2005 ; 58: 169–70.
42. 42 Newton JL, Gibson GJ, Tomlinson M, Wilton K, Jones D. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology 2006 ; 44: 91–8.
43. 43 Cordoba J, Cabrera J, Lataif L, Penev P, Zee P, Blei AT. High prevalence of sleep disturbance in cirrhosis. Hepatology 1998 ; 27: 339–45.
44. 44 Muller‐Preuss P, Rupprecht R, Lancel M. The effects of the neuroactive steroid 3‐alpha,5‐alpha‐THDOC on sleep in the rat. NeuroReport 2002 ; 13: 487–90.
45. 45 Söderpalm AH, Lindsey S, Purdy RH, Hauger R, De Wit H. Administration of progesterone produces mild sedative‐like effects in men and women. Psychoneuroendocrinology 2004 ; 29: 339–54.
46. 46 Freeman EW, Purdy RH, Coutifaris C. Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. Neuroendocrinology 1993 ; 58: 478–84.
47. 47 Sundström I, Andersson A, Nyberg S, Ashbrook D, Purdy RH, Bäckström T. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 1998 ; 67: 126–38.